Disease/Infection News

RSS

Mpox inactivated in 60 seconds with Σ-MM™ & patient friendly collection swab

In the wake of the global Mpox outbreak in non-endemic countries in 2022, the medical community has been searching for safer and more efficient ways to transport and test virus samples, especially from patients in areas with limited biological containment facilities.

From Medical Wire 6 Sep 2024

How mosquito spit could help develop therapies for arboviral diseases

You might guess it'd be tough to extract saliva from a mosquito. And you'd be correct. Yet, because mosquitos spread disease via saliva, it's critical to sample and study.

5 Sep 2024

Mucosal COVID-19 boosters outperform mRNA shots in preventing upper airway infections

Aerosolized mucosal vaccines show promise in controlling SARS-CoV-2, offering greater protection and immune response than intramuscular bivalent mRNA boosters.

5 Sep 2024

Lipidomics and metabolomics as potential biomarkers for breast cancer progression

This review highlights the potential of lipidomic and metabolomic biomarkers in predicting breast cancer prognosis and therapy response, enhancing patient care.

5 Sep 2024

Semaglutide reduced mortality in obese patients by lowering infection-related deaths during COVID-19 pandemic

Semaglutide significantly reduces all-cause mortality in non-diabetic obese patients, particularly by lowering infection-related deaths during the COVID-19 pandemic. However, the study's findings should be interpreted with caution due to potential competing risks and unique pandemic circumstances.

5 Sep 2024

Promising new strategy to combat fungal infections

A group of Brazilian researchers has found a potential target for novel therapeutic strategies to combat fungal infections – more specifically, those caused by Aspergillus fumigatus. An article reporting the discovery is published in the journal Communications Biology.

5 Sep 2024

Bats and birds in Madrid are top carriers of zoonotic pathogens, study reveals

Researchers characterize potential zoonotic pathogens present in fecal samples of urban vertebrate species.

4 Sep 2024

Akebia Therapeutics to present at upcoming investor conferences

Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo Healthcare Conference on September 4-6, 2024 in Boston and H.C. Wainwright 26th Annual Global Investment Conference on September 9-11, 2024 in New York.

From Akebia Therapeutics 4 Sep 2024

Study aims to find new ways of alleviating the long-term effects of COVID-19

An innovative study for the treatment of post-COVID syndrome (PCS) is starting under the direction of Frankfurt University Hospital’s Department of Infectious Diseases.

4 Sep 2024

Obesity identified as a significant risk factor for COVID-19 infection

A new study by investigators from Mass General Brigham has found that obesity may be an important risk factor for infection from the virus that causes COVID-19.

4 Sep 2024

Cholera crisis deepens with higher cases and fatalities in 2023

The World Health Organization (WHO) has published global cholera statistics for 2023, showing an increase in cases and deaths.

4 Sep 2024

WHO unveils global framework for investigating origins of novel pathogens

With the support of the Scientific Advisory Group for the Origins of Novel Pathogens (SAGO), the World Health Organization (WHO) has published a global framework to help Member States comprehensively investigate the origins of new and re-emerging pathogens.

4 Sep 2024

Immune cells prevent the lungs' protective barrier from healing after viral infections

Investigators involved in a multicenter study co-led by Cedars-Sinai discovered a pathway by which immune cells prevent the lungs' protective barrier from healing after viral infections like COVID-19.

4 Sep 2024

Study finds Lassa fever infection rates to be far greater than previously believed

The first-ever detailed estimate of the real damage done by Lassa fever, a virus endemic to West Africa, has found that it infects 2.7 million people a year, ten times more than health agencies had assumed.

4 Sep 2024

Lifestyle interventions in patients after colorectal cancer treatment

A recent RCT reveals the HEAL ABC intervention is feasible for 87% of colorectal cancer survivors, supporting healthy lifestyle changes and improved well-being.

4 Sep 2024

Understanding the impact of BMI on colorectal cancer risk in Asia

Researchers report that body mass index values in Asians population may predict the risk of developing colorectal cancer.

4 Sep 2024

Scientists uncover shared gene expression patterns in aging and psychiatric disorders

Researchers reveal how aging and psychiatric disorders converge at the cellular level in the orbitofrontal cortex, identifying key gene expression changes that could lead to new therapies.

4 Sep 2024

A novel therapeutic option for HER2-positive extramammary Paget disease

The research article presents a comprehensive evaluation of the human epidermal growth factor receptor 2 (HER2) status in extramammary Paget disease (EMPD) and explores the therapeutic potential of disitamab vedotin (DV), a novel humanized anti-HER2 antibody-drug conjugate (ADC), for this rare adenocarcinoma.

4 Sep 2024

Seasonal patterns in Valley fever cases reveal climate-driven risks

Valley fever is an emerging fungal disease in the western United States that most often causes flu-like symptoms, but can also cause dangerous or even deadly complications. By analyzing data on reported cases of Valley fever in California, which have increased dramatically over the last two decades, researchers from the University of California San Diego and the University of California, Berkeley, have identified seasonal patterns that could help individuals and public health officials better prepare for future surges in Valley fever cases.

4 Sep 2024

New approach to treat post-COVID symptoms

In a world still grappling with the aftermath of the COVID-19 pandemic, a team of international researchers has proposed a novel approach to treating the persistent symptoms that plague many survivors of viral infections. The study, published on 30 August 2024 in Brain Medicine (ISSN: 2997-2639, Genomic Press, New York), outlines a multimodal treatment strategy that could offer hope to millions suffering from post-acute infectious syndromes (PAIS), including the condition commonly known as Long COVID.

4 Sep 2024